Log in

NASDAQ:XLRNAcceleron Pharma Stock Price, Forecast & News

-0.68 (-0.73 %)
(As of 08/13/2020 04:00 PM ET)
Today's Range
Now: $92.20
50-Day Range
MA: $100.93
52-Week Range
Now: $92.20
Volume353,000 shs
Average Volume680,413 shs
Market Capitalization$5.52 billion
P/E RatioN/A
Dividend YieldN/A
Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis. The company is also developing and sotatercept for the treatment of patients with pulmonary arterial hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Read More
Acceleron Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.28 out of 5 stars

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:XLRN



Sales & Book Value

Annual Sales$73.99 million
Book Value$8.47 per share


Net Income$-124,860,000.00
Net Margins-157.84%


Market Cap$5.52 billion
Next Earnings Date11/4/2020 (Estimated)
-0.68 (-0.73 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XLRN News and Ratings via Email

Sign-up to receive the latest news and ratings for XLRN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Acceleron Pharma (NASDAQ:XLRN) Frequently Asked Questions

How has Acceleron Pharma's stock been impacted by Coronavirus?

Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XLRN shares have increased by 9.3% and is now trading at $92.20.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Acceleron Pharma?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 1 sell rating, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Acceleron Pharma

When is Acceleron Pharma's next earnings date?

Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Acceleron Pharma

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) announced its earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.21. The biopharmaceutical company earned $39.75 million during the quarter, compared to analysts' expectations of $30.08 million. Acceleron Pharma had a negative net margin of 157.84% and a negative return on equity of 31.25%. The company's revenue for the quarter was up 43.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.34) earnings per share.
View Acceleron Pharma's earnings history

What price target have analysts set for XLRN?

13 brokerages have issued 12 month target prices for Acceleron Pharma's shares. Their forecasts range from $71.00 to $140.00. On average, they anticipate Acceleron Pharma's stock price to reach $117.92 in the next year. This suggests a possible upside of 27.9% from the stock's current price.
View analysts' price targets for Acceleron Pharma

What are Wall Street analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:
  • 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (1/16/2020)
  • 2. HC Wainwright analysts commented, "We are lowering our price target to $68 from $69 due to the discontinuation of ACE-083 for FSHD. Our $68 price target is based on probability-adjusted revenue forecasts for luspatercept, the company’s earlier stage pipeline, and estimated year-end cash." (9/17/2019)

Has Acceleron Pharma been receiving favorable news coverage?

News stories about XLRN stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Acceleron Pharma earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Acceleron Pharma

Are investors shorting Acceleron Pharma?

Acceleron Pharma saw a decrease in short interest in July. As of July 31st, there was short interest totaling 3,120,000 shares, a decrease of 6.9% from the July 15th total of 3,350,000 shares. Based on an average daily volume of 692,400 shares, the short-interest ratio is presently 4.5 days. Currently, 6.2% of the shares of the stock are short sold.
View Acceleron Pharma's Short Interest

Who are some of Acceleron Pharma's key competitors?

What other stocks do shareholders of Acceleron Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Advanced Micro Devices (AMD), Gilead Sciences (GILD), NVIDIA (NVDA), Incyte (INCY), Pfizer (PFE), AbbVie (ABBV), Corcept Therapeutics (CORT), Cisco Systems (CSCO) and Exelixis (EXEL).

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the following people:
  • Mr. Habib J. Dable, CEO, Pres & Director (Age 50)
  • Dr. Thomas P. Maniatis, Co-Founder, Member of Scientific Advisory Board & Director (Age 76)
  • Mr. Kevin F. McLaughlin, Sr. VP, CFO & Treasurer (Age 63)
  • Dr. Ravindra Kumar, Chief Scientific Officer & Sr. VP (Age 59)
  • Dr. John D. Quisel, Exec. VP, Chief Bus. Officer & Sec. (Age 48)

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Who are Acceleron Pharma's major shareholders?

Acceleron Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (12.82%), TimesSquare Capital Management LLC (1.81%), Goldman Sachs Group Inc. (0.82%), Candriam Luxembourg S.C.A. (0.71%), Bank of New York Mellon Corp (0.55%) and New York State Common Retirement Fund (0.44%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango.
View institutional ownership trends for Acceleron Pharma

Which major investors are selling Acceleron Pharma stock?

XLRN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Candriam Luxembourg S.C.A., State of Wisconsin Investment Board, Goldman Sachs Group Inc., Prudential Financial Inc., UBS Group AG, SG Americas Securities LLC, and Bank of New York Mellon Corp. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Corp /De/ Celgene, Habib J Dable, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar, and Sujay Kango.
View insider buying and selling activity for Acceleron Pharma

Which major investors are buying Acceleron Pharma stock?

XLRN stock was bought by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., New York State Common Retirement Fund, Rhenman & Partners Asset Management AB, Sofinnova Investments Inc., Principal Financial Group Inc., State Board of Administration of Florida Retirement System, WINTON GROUP Ltd, and Virtu Financial LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene, and Joseph S Zakrzewski.
View insider buying and selling activity for Acceleron Pharma

How do I buy shares of Acceleron Pharma?

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of XLRN stock can currently be purchased for approximately $92.20.

How big of a company is Acceleron Pharma?

Acceleron Pharma has a market capitalization of $5.52 billion and generates $73.99 million in revenue each year. The biopharmaceutical company earns $-124,860,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.

What is Acceleron Pharma's official website?

The official website for Acceleron Pharma is www.acceleronpharma.com.

How can I contact Acceleron Pharma?

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.